Our leadership team has experience from discovery through to commercialisation
Chief Executive Director
Mr Glyn Edwards was appointed to the Board of Directors as Chief Executive Officer in April 2012. Mr Edwards has a wealth of experience garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles.
Prior to joining Summit, he was interim Chief Executive Officer of the UK trade body the BioIndustry Association (BIA) and Chief Executive Officer at Antisoma plc for 13 years, and Vice President of Business Development at Therapeutic Antibodies Ltd. Mr Edwards holds a BSc in biochemistry from Bristol University and an MSc in economics from the London Business School.
Chief Operating Officer, Chief Medical Officer and President of R&D
Dr David Roblin joined as our Chief Operating Officer and President of Research and Development in early 2017 and expanded his role to become Chief Medical Officer in May 2017. Dr Roblin has been acting as a research and development adviser to Summit since 2014.
Dr Roblin is an experienced scientist and physician, with a distinguished career in the pharmaceutical industry. He and his units have brought many medicines in several therapy areas through R&D to commercialisation, including in anti-infectives azithromycin, ciprofloxacin, moxifloxacin, voriconazole and maraviroc.
Dr Roblin has previously served as the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London (2014 – 2017). Prior to this, he was Head of Research and Chief Medical Officer for Europe R&D at Pfizer Inc. from 2008 to 2011 and was Head of Therapy Area for Anti-infectives at Bayer AG from 1997 to 1999. He is also a non-executive director of Sosei PLC and sits on a variety of committees at Wellcome, on the UK Biomedical Catalyst Fund and the LEO Foundation prize committee.
Dr Roblin has a degree in biochemistry from University of London and qualified in Medicine from St George’s Hospital, London. He is a Fellow of the Royal College of Physicians, Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s.
Chief Commercial Officer And Svp, R&D
Dr Elger joined our company in June of 2015. Previously, he served as the Chief Financial Officer and Corporate Development Officer of Genkyotex, Chief Financial Officer of e-Therapeutics plc and Vice President, Marketing and Communications of Antisoma. He earned his PhD in cancer biology from the University of Oxford and BA in medicine also from the University of Oxford.
Chief Scientific Officer and SVP, R&D
Dr Vickers joined our company in 2003 and has served as our Chief Scientific Officer, Antimicrobials, since October 2013. During his time at our company, Dr Vickers has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs, including our antibiotic program for the treatment of CDI.
Prior to joining our company, Dr Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine’s College in Oxford. Dr Vickers received a PhD in organic chemistry from the University of Reading and a BSc in chemistry from King’s College London.
Head of Research and SVP
Dr Dave Powell joined Summit from GSK where he served as Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.
Dr Powell held a number of positions of increasing seniority in his time at GSK. As part of his work there, he participated in antibiotic discovery, assay development, high throughput screening design and implementation, and lead optimisation support. In his most recent role at GSK, he led a collaboration with the Crick Institute, in addition to providing support to GSK’s ‘Discovery Partnerships with Academia’ team which collaborated with academic groups in downstream drug discovery. He was awarded a BSc and MSc from the National University of Ireland Galway, before completing a PhD in biochemistry at Cardiff University.